INSYS Therapeutics Reports Fourth Quarter and Full Year 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
INSYS Therapeutics (INSY) PT Lowered to $7 at RBC Capital
March 8, 2019 6:29 AM ESTRBC Capital analyst Randall Stanicky lowered the price target on INSYS Therapeutics (NASDAQ: INSY) to $7.00 (from $9.00) while maintaining a Outperform rating.
... MoreInsys Therapeutics (INSY) Misses Q4 EPS by 8c
March 7, 2019 4:26 PM ESTInsys Therapeutics (NASDAQ: INSY) reported Q4 EPS of ($0.37), $0.08 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $16.4 million versus the consensus estimate of $18.1 million.
For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.
... More